NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
11 trialsNCT06303713 2026-04-08
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05079698 2026-04-07
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07054346 2026-04-01
LUTACT
University of California, San Francisco
Phase 1 Recruiting
NCT04886986 2026-03-31
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT05162573 2025-12-10
PROQURE-1
The Netherlands Cancer Institute
Phase 1 Completed
NCT07223034 2025-11-04
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05613894 2025-10-31
CaboLu
University of Utah
Phase 1 Recruiting
NCT06943495 2025-09-09
PRODIGY-2
CHU de Quebec-Universite Laval
Phase 1 Recruiting
NCT03805594 2025-02-25
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed